Abstract
Background Phosphodiesterase-5-inhibitors are vasoactive drugs used in the treatment of erectile dysfunction and pulmonary hypertension. Their beneficial effects in the pulmonary vasculature are widely described, but it remained unclear, how they influence cardiac performance. In the present study we investigated the effects of the phosphodiesterase5-inhibitor vardenafil on myocardial and vasomotor function in a rat model.
Highlights
Open AccessA selective phosphodiesterase-5-inhibitor, on cardiovascular function in a rat model
Phosphodiesterase-5-inhibitors are vasoactive drugs used in the treatment of erectile dysfunction and pulmonary hypertension
3rd International Conference on cGMP Generators, Effectors and Therapeutic Implications Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here.
Summary
A selective phosphodiesterase-5-inhibitor, on cardiovascular function in a rat model. Published: 25 July 2007 BMC Pharmacology 2007, 7(Suppl 1):P39 doi:10.1186/1471-2210-7-S1-P39. 3rd International Conference on cGMP Generators, Effectors and Therapeutic Implications Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
